Session » SLE – Etiology and Pathogenesis Poster

Date: Sunday, November 13, 2022

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2022

9:00AM-10:30AM: Abstract Number: 0670

A Short Allelic Epitope Coded by HLA-DRB1*03:01 Activates a Systemic Lupus Erythematosus Cell Aberration Cascade

9:00AM-10:30AM: Abstract Number: 0663

Anti-Erythrocyte Antibodies in Childhood Onset Systemic Lupus Erythematosus

9:00AM-10:30AM: Abstract Number: 0639

Association of Gut Microbiome Streptococcus, Health Status, Cytokines, and HLA Class in Anti-Ro+ Mothers of Children with Neonatal Lupus: Insights into Progression of Clinical Autoimmunity

9:00AM-10:30AM: Abstract Number: 0656

Association Study Identified HLA-DQA1 as a Genetic Risk of Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension

9:00AM-10:30AM: Abstract Number: 0635

Blood RNA-sequencing Reveals Complex Immune Dysregulation in ANA-positive Individuals with Distinct Profiles Preceding Progression to SLE versus Stable Autoimmunity

9:00AM-10:30AM: Abstract Number: 0659

Comprehensive Proteomic Screen of Murine Lupus Serum and Cerebrospinal Fluid Uncovers Diagnostic and Therapeutic Targets

9:00AM-10:30AM: Abstract Number: 0667

Correlation Matrices Visualize Differential Degree of Cell and Pathway Heterogeneity in Skin of Cutaneous Lupus Erythematosus Treatment Subgroups

9:00AM-10:30AM: Abstract Number: 0661

Cutaneous Type I IFN Responses in Systemic Lupus Erythematosus Are Associated with Inflammatory Phenotype and Altered Wound Healing Function of Lupus Fibroblasts from Non-Lesional Skin

9:00AM-10:30AM: Abstract Number: 0657

DB-2304, a Novel anti-BDCA2 Monoclonal Antibody Drug Conjugate, Displayed Great Potency in Suppression of pDC Functions

9:00AM-10:30AM: Abstract Number: 0664

Development of a Novel Gene Expression-based Molecular Score That Characterizes Individual Lupus Patients

9:00AM-10:30AM: Abstract Number: 0668

Differential Expression of Interferon Related Genes in SLE Patients of Asian and European Ancestries Abstract

9:00AM-10:30AM: Abstract Number: 0630

Ferroptosis of CD163+ Tissue Infiltrating Macrophages in Lupus Nephritis

9:00AM-10:30AM: Abstract Number: 0666

HRES-1/Rab4 Controls the Overexpression of CD38 and Depletion of IL-2 in CD4+ T Cells; Potential Involvement in Proinflammatory Lineage Development in SLE

9:00AM-10:30AM: Abstract Number: 0638

Identification of New Candidate Drugs for SLE Using a Drug Repurposing Transcriptomic Approach on Blood, Skin and Kidney Samples from 3439 Patients

9:00AM-10:30AM: Abstract Number: 0633

Identification of Systemic Lupus Erythematosus Endotypes by Analysis of Inflammatory and Immunologic Gene Expression Signatures

9:00AM-10:30AM: Abstract Number: 0641

IL-4 Receptor Signaling and IKAROS Transcriptomic Program Maintains Naïve B-cell Quiescence and Antagonizes SLE

9:00AM-10:30AM: Abstract Number: 0640

Immune Cell Heterogeneity in Lupus Nephritis Kidneys and Its Relation to Histopathological Features

9:00AM-10:30AM: Abstract Number: 0651

Inflammatory Dendritic Cell Drive Intra-renal T Cells to Double-negative T Cell in Lupus Nephritis

9:00AM-10:30AM: Abstract Number: 0658

Integrative Analysis of Cell-Specific Human Endogenous Retrovirus Expression and Host Gene Expression Identifies Associations with Clinical SLE Phenotypes

9:00AM-10:30AM: Abstract Number: 0653

JAK Inhibitors Counteract Cellular Toxicity of Hydroxychloroquine in Vitro

9:00AM-10:30AM: Abstract Number: 0644

Long-lived Plasma Cells in the Lupus Bone Marrow Are Imprinted by Interferon

9:00AM-10:30AM: Abstract Number: 0645

Lupus Fibroblasts from Non-lesional Skin Exhibit Exaggerated Responses to Inflammatory Cytokines and Upregulate Pro-fibrotic Collagens in Patients with Scarring Lesions

9:00AM-10:30AM: Abstract Number: 0654

Lymphatic Dysfunction and Immune Activation in Lupus

9:00AM-10:30AM: Abstract Number: 0646

Modulation of Type I IFN Production and Regulatory T Cells by the PKGI/ROCK Signaling Pathway

9:00AM-10:30AM: Abstract Number: 0662

Partial Correlations Network Models Show Th1, Th2 and Th17 Responses to Be Interlinked in Dermal Pathogenesis of Cutaneous Lupus Erythematous

9:00AM-10:30AM: Abstract Number: 0648

Pathogenic Anti-C1q Antibodies Potentiate Activation of the Classical Complement Pathway in a Subset of Lupus Nephritis Patients

9:00AM-10:30AM: Abstract Number: 0631

Perfluoroalkyl Substances and Community Vulnerability: Associations with Lupus-Related Autoantibodies and Disease

9:00AM-10:30AM: Abstract Number: 0649

Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity

9:00AM-10:30AM: Abstract Number: 0655

Proteomic Analysis of Histological Lesions Lupus Nephritis Identifies an Inflammatory Signature of Fibrous Crescents

9:00AM-10:30AM: Abstract Number: 0637

Reduced IgG Sialic Acid Content: A Distinctive Characteristic of Symptomatic Anti-Nuclear Antibodies Positive Individuals

9:00AM-10:30AM: Abstract Number: 0665

Screening for Neurocognitive Demands in Childhood-onset Systemic Lupus Erythematosus Patients Using Pediatric Automated Neuropsychological Assessment Metrics and Association with Magnetic Resonance Imaging

9:00AM-10:30AM: Abstract Number: 0652

Serum from Patients with SLE and Anti-MDA5 Antibody-Positive Dermatomyositis Induce Shared Monocyte Cytokine Signature Through Type 1 Interferon Pathway

9:00AM-10:30AM: Abstract Number: 0660

Serum Proteins and Metabolites Differ in SLE Patients with Coronary Microvascular Dysfunction (CMD) as Determined by Cardiac MRI Compared to SLE Patients Without CMD – a Pilot Study

9:00AM-10:30AM: Abstract Number: 0636

Serum Soluble Mediator Signatures of Lupus Nephritis Histological Features and Response to Treatment

9:00AM-10:30AM: Abstract Number: 0632

Single-cell Multiomic Profiling Differentiates Ancestral B Cell Pathologies Contributing to Lupus Disease Activity

9:00AM-10:30AM: Abstract Number: 0642

SLAMF6-SAP Signaling Unit Is Increased in SLE T Follicular Helper Cells

9:00AM-10:30AM: Abstract Number: 0643

Subsetting SLE Patients Based on DNA Methylation at the Time of Disease Flare

9:00AM-10:30AM: Abstract Number: 0650

The Association of Urinary C9 to CD59 Ratio with Tubulointerstitial Fibrosis in Lupus Nephritis

9:00AM-10:30AM: Abstract Number: 0629

The Cellular Metabolism of SLE NK Cells Is Primarily Altered at the Level of Mitochondrial Respiration

9:00AM-10:30AM: Abstract Number: 0634

Total Interstitial Inflammation Predicts Chronic Kidney Disease Progression in Patients with Lupus Nephritis

9:00AM-10:30AM: Abstract Number: 0647

Transcriptomic Analysis of Lupus Nephritis Kidneys Identifies Molecular Endotypes

9:00AM-10:30AM: Abstract Number: 0669

Understanding How Type I Interferon Modulates Langerhans Cell ADAM17 to Promote Photosensitivity in Lupus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].